PLUR Pluri: Rentabilitas operasi

Lambang korporat lan logo pluri-biotech.com (PLUR)

The absence of stable operating income and a reliance on clinical potential define the current state of Pluri Inc. (PLUR). The operating profitability of operational processes demonstrates the issuer's maturity dynamics, where the -2341.10 mark reflects the latest data. Biotech risks are mitigated by the application of cellular patents in food technology. The synthesis of medicine and agrotech via the cell expansion platform effectively distributes commercial threats.

Pluri Inc (PLUR): Margin bathi operasi saka 28.04.2023 nganti 19.11.2026

Rincian analitis lan laporan data perusahaan Pluri Inc (PLUR)

- rega lan prakiraan konsensus rega:
Pambiji fundamental perusahaan:Pluri Inc, PLUR
Produk merek Pluristem Therapeutics

Operating margin measures core business efficiency by calculating the ratio of earnings before interest and taxes to revenue, demonstrating the company's ability to generate cash flow. Analyzing the operating profit margin history allows for an assessment of Pluri Inc. (PLUR) resilience against pressure from pharma behemoths developing more affordable drugs within the high-risk cell biotechnology sector.